DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SAN DIEGO, Feb. 27, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, March 5, 2018 at 5:00 p.m. ET to report its fourth quarter and full year 2017 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 7589759. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. This platform uniquely enables the single-cell selection of a precisely engineered iPSC clone and the subsequent creation and maintenance of a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for generating homogeneous cell products in quantities that support the treatment of many thousands of patients in an off-the-shelf manner. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as other NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy to promote immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
